Intrexon Stock Price, News & Analysis (NYSE:XON)

$13.28 0.16 (1.22 %)
(As of 12/11/2017 02:10 AM ET)
Previous Close$13.12
Today's Range$13.10 - $13.43
52-Week Range$10.26 - $30.96
Volume783,800 shs
Average Volume1.14 million shs
Market Capitalization$1.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32

About Intrexon (NYSE:XON)

Intrexon logoIntrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Receive XON News and Ratings via Email

Sign-up to receive the latest news and ratings for XON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:XON
CUSIPN/A
Phone+1-301-5569809

Debt

Debt-to-Equity Ratio0.01%
Current Ratio2.05%
Quick Ratio1.85%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$190.93 million
Price / Sales8.40
Cash FlowN/A
Price / CashN/A
Book Value$4.80 per share
Price / Book2.77

Profitability

Trailing EPS($1.12)
Net Income$-186,610,000.00
Net Margins-66.88%
Return on Equity-18.68%
Return on Assets-11.34%

Miscellaneous

Employees935
Outstanding Shares120,720,000

Intrexon (NYSE:XON) Frequently Asked Questions

What is Intrexon's stock symbol?

Intrexon trades on the New York Stock Exchange (NYSE) under the ticker symbol "XON."

How were Intrexon's earnings last quarter?

Intrexon Corporation (NYSE:XON) released its quarterly earnings data on Wednesday, May, 10th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.04. The biotechnology company had revenue of $53.70 million for the quarter, compared to the consensus estimate of $49.08 million. Intrexon had a negative net margin of 66.88% and a negative return on equity of 18.68%. Intrexon's revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.55) EPS. View Intrexon's Earnings History.

When will Intrexon make its next earnings announcement?

Intrexon is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Intrexon.

Where is Intrexon's stock going? Where will Intrexon's stock price be in 2017?

6 Wall Street analysts have issued twelve-month price targets for Intrexon's stock. Their forecasts range from $21.00 to $57.00. On average, they anticipate Intrexon's share price to reach $38.50 in the next year. View Analyst Ratings for Intrexon.

Who are some of Intrexon's key competitors?

Who are Intrexon's key executives?

Intrexon's management team includes the folowing people:

  • Randal J. Kirk, Chairman of the Board, Chief Executive Officer (Age 63)
  • Thomas D. Reed Ph.D., Founder, Chief Science Officer (Age 51)
  • Rick L. Sterling CPA, Chief Financial Officer (Age 53)
  • Thomas Bostick Ph.D., Chief Operating Officer
  • Joel Liffmann, Senior Vice President - Finance (Age 56)
  • Jack Anthony Bobo, Senior Vice President, Chief Communications Officer (Age 51)
  • Ena Chan Cratsenburg, Senior Vice President - Consumer Sector (Age 48)
  • Jeffrey T. Perez, Senior Vice President — Intellectual Property Affairs (Age 45)
  • Christopher Basta, Vice President - Investor Relations
  • Donald P. Lehr, Chief Legal Officer (Age 42)

Who owns Intrexon stock?

Intrexon's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Third Security LLC (46.88%), Iridian Asset Management LLC CT (3.06%), First Trust Advisors LP (1.32%), Peregrine Capital Management LLC (0.48%), Bank of New York Mellon Corp (0.20%) and Schwab Charles Investment Management Inc. (0.16%). Company insiders that own Intrexon stock include Andrew J Last, Dean J Mitchell, Donald P Lehr, Fred Hassan, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk and Robert B Shapiro. View Institutional Ownership Trends for Intrexon.

Who sold Intrexon stock? Who is selling Intrexon stock?

Intrexon's stock was sold by a variety of institutional investors in the last quarter, including Third Security LLC, Frontier Capital Management Co. LLC, Iridian Asset Management LLC CT, Stifel Financial Corp, Lagoda Investment Management L.P., Advisors Asset Management Inc., Schwab Charles Investment Management Inc. and Ladenburg Thalmann Financial Services Inc.. View Insider Buying and Selling for Intrexon.

Who bought Intrexon stock? Who is buying Intrexon stock?

Intrexon's stock was acquired by a variety of institutional investors in the last quarter, including Commonwealth Equity Services Inc, Peregrine Capital Management LLC, GSA Capital Partners LLP, JPMorgan Chase & Co., First Trust Advisors LP, First Washington CORP, Trellus Management Company LLC and Fox Run Management L.L.C.. Company insiders that have bought Intrexon stock in the last two years include Andrew J Last, Dean J Mitchell, Donald P Lehr, Fred Hassan, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk and Robert B Shapiro. View Insider Buying and Selling for Intrexon.

How do I buy Intrexon stock?

Shares of Intrexon can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intrexon's stock price today?

One share of Intrexon stock can currently be purchased for approximately $13.28.

How big of a company is Intrexon?

Intrexon has a market capitalization of $1.60 billion and generates $190.93 million in revenue each year. The biotechnology company earns $-186,610,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Intrexon employs 935 workers across the globe.

How can I contact Intrexon?

Intrexon's mailing address is 1750 Kraft Dr Ste 1400, BLACKSBURG, VA 24060-6147, United States. The biotechnology company can be reached via phone at +1-301-5569809 or via email at [email protected]


MarketBeat Community Rating for Intrexon (XON)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about Intrexon and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intrexon (NYSE:XON) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.712.832.63
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.50$38.50$43.80$42.29
Price Target Upside: 225.99% upside225.99% upside102.31% upside119.32% upside

Intrexon (NYSE:XON) Consensus Price Target History

Price Target History for Intrexon (NYSE:XON)

Intrexon (NYSE:XON) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Northland SecuritiesReiterated RatingBuy$21.00N/AView Rating Details
11/10/2017Bank of AmericaLower Price TargetNeutral$25.00 -> $21.00N/AView Rating Details
11/10/2017Stifel NicolausBoost Price TargetBuy$39.00 -> $57.00N/AView Rating Details
10/6/2017Griffin SecuritiesReiterated RatingBuy$55.00N/AView Rating Details
10/5/2017JMP SecuritiesReiterated RatingOutperform$42.00N/AView Rating Details
3/14/2017WunderlichLower Price TargetBuy$50.00 -> $35.00HighView Rating Details
11/11/2016J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
3/1/2016MizuhoReiterated RatingNeutral$28.00 -> $29.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Intrexon (NYSE:XON) Earnings History and Estimates Chart

Earnings by Quarter for Intrexon (NYSE:XON)

Intrexon (NYSE XON) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.32)N/AView Earnings Details
8/9/2017Q2 2017($0.21)($0.16)$57.17 million$54.40 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.22)($0.26)$49.08 million$53.70 millionViewN/AView Earnings Details
3/1/2017Q416($0.23)($0.37)$52.53 million$46.00 millionViewListenView Earnings Details
11/9/2016Q316($0.21)($0.24)$51.70 million$48.99 millionViewListenView Earnings Details
8/9/2016Q216($0.26)($0.42)$53.78 million$52.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.20)($0.55)$46.26 million$43.40 millionViewListenView Earnings Details
2/29/2016Q415($0.18)($0.28)$41.82 million$41.50 millionViewListenView Earnings Details
11/9/2015Q3($0.21)($0.34)$40.84 million$53.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.04)$0.01$55.93 million$44.90 millionViewListenView Earnings Details
5/11/2015Q115($0.12)$0.25$32.90 million$33.80 millionViewListenView Earnings Details
3/2/2015Q414($0.16)$0.18$26.11 million$31.10 millionViewN/AView Earnings Details
11/13/2014Q314($0.16)($0.53)$19.40 million$21.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$9.39 million$11.80 millionViewN/AView Earnings Details
5/7/2014Q1$0.06$0.04$11.25 million$7.90 millionViewN/AView Earnings Details
3/31/2014Q413($0.14)($0.13)$8.38 million$7.10 millionViewN/AView Earnings Details
11/7/2013($0.03)$0.15$9.79 million$6.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Intrexon (NYSE:XON) Earnings Estimates

2017 EPS Consensus Estimate: ($0.99)
2018 EPS Consensus Estimate: ($0.92)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.19)($0.19)($0.19)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.35)($0.35)($0.35)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.23)($0.23)($0.23)
Q3 20181($0.24)($0.24)($0.24)
Q4 20181($0.24)($0.24)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intrexon (NYSE:XON)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Intrexon (NYSE XON) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 55.10%
Institutional Ownership Percentage: 77.49%
Insider Trades by Quarter for Intrexon (NYSE:XON)
Institutional Ownership by Quarter for Intrexon (NYSE:XON)

Intrexon (NYSE XON) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017Andrew J LastCOOBuy2,000$12.10$24,200.00View SEC Filing  
8/22/2017Robert B ShapiroDirectorBuy2,850$17.50$49,875.00View SEC Filing  
8/14/2017Andrew J LastCOOBuy2,000$19.99$39,980.00View SEC Filing  
8/11/2017Dean J MitchellDirectorBuy5,000$18.33$91,650.00View SEC Filing  
8/11/2017Donald P LehrInsiderBuy1,094$18.33$20,053.02View SEC Filing  
8/11/2017Jeffrey Thomas PerezSVPBuy1,000$17.89$17,890.00View SEC Filing  
8/11/2017Randal J KirkCEOBuy132,625$18.85$2,499,981.25View SEC Filing  
12/13/2016Randal J KirkCEOBuy34,606$28.90$1,000,113.40View SEC Filing  
12/12/2016Joel D LiffmanSVPBuy8,500$28.62$243,270.00View SEC Filing  
12/1/2016Fred HassanDirectorBuy6,900$29.02$200,238.00View SEC Filing  
8/29/2016Nir NimrodiSVPBuy4,000$26.12$104,480.00View SEC Filing  
5/13/2016Randal J KirkCEOBuy41,830$23.92$1,000,573.60View SEC Filing  
12/11/2015Randal J KirkCEOBuy124,475$29.85$3,715,578.75View SEC Filing  
12/7/2015Randal J KirkCEOBuy237,525$30.69$7,289,642.25View SEC Filing  
12/4/2015Suma KrishnanSVPSell20,900$35.66$745,294.00View SEC Filing  
1/27/2015Randal J KirkCEOBuy555,556$27.00$15,000,012.00View SEC Filing  
5/13/2014Donald LehrInsiderBuy1,850$15.99$29,581.50View SEC Filing  
5/13/2014Randal KirkCEOBuy65,173$15.19$989,977.87View SEC Filing  
5/9/2014Kelly HuangSVPBuy3,200$15.78$50,496.00View SEC Filing  
5/9/2014Krish KrishnanCOOBuy20,900$14.21$296,989.00View SEC Filing  
3/27/2014Randal KirkCEOBuy243,001$25.72$6,249,985.72View SEC Filing  
3/4/2014Gregory Ian FrostSVPBuy100,000$25.95$2,595,000.00View SEC Filing  
8/13/2013Jeffrey B KindlerDirectorBuy33,000$16.00$528,000.00View SEC Filing  
8/13/2013Randal J KirkCEOBuy1,887,500$16.00$30,200,000.00View SEC Filing  
8/13/2013Thomas D ReedInsiderBuy1,800$16.00$28,800.00View SEC Filing  
8/13/2013Thomas R KasserSVPBuy5,000$16.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intrexon (NYSE XON) News Headlines

Source:
DateHeadline
Contrasting Intrexon (XON) and Its PeersContrasting Intrexon (XON) and Its Peers
www.americanbankingnews.com - December 9 at 8:04 AM
Financial Survey: Intrexon (XON) versus Its CompetitorsFinancial Survey: Intrexon (XON) versus Its Competitors
www.americanbankingnews.com - December 9 at 1:22 AM
Critical Analysis: Intrexon (XON) versus The CompetitionCritical Analysis: Intrexon (XON) versus The Competition
www.americanbankingnews.com - December 8 at 5:14 PM
Chester County gene therapy company seeking $10.5M from public stock saleChester County gene therapy company seeking $10.5M from public stock sale
www.bizjournals.com - December 8 at 4:17 PM
Intrexon Corporation (XON) Expected to Post Quarterly Sales of $48.79 MillionIntrexon Corporation (XON) Expected to Post Quarterly Sales of $48.79 Million
www.americanbankingnews.com - December 2 at 6:00 AM
Head to Head Analysis: Intrexon (XON) and Codexis (CDXS)Head to Head Analysis: Intrexon (XON) and Codexis (CDXS)
www.americanbankingnews.com - December 1 at 11:42 PM
Intrexon Corporation (XON) Receives Consensus Recommendation of "Hold" from BrokeragesIntrexon Corporation (XON) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 30 at 5:56 PM
 Analysts Anticipate Intrexon Corporation (XON) Will Post Earnings of -$0.31 Per Share Analysts Anticipate Intrexon Corporation (XON) Will Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - November 30 at 5:26 PM
Head-To-Head Contrast: Intrexon (XON) vs. The CompetitionHead-To-Head Contrast: Intrexon (XON) vs. The Competition
www.americanbankingnews.com - November 28 at 11:24 PM
Intrexon Corporation (XON)’s Earnings Grew 24.8%, Is It Enough?Intrexon Corporation (XON)’s Earnings Grew 24.8%, Is It Enough?
finance.yahoo.com - November 28 at 11:41 AM
Intrexon Announces Key Management Appointments - PR Newswire (press release)Intrexon Announces Key Management Appointments - PR Newswire (press release)
www.prnewswire.com - November 27 at 3:32 PM
Intrexon Announces Key Management AppointmentsIntrexon Announces Key Management Appointments
finance.yahoo.com - November 27 at 8:18 AM
OptiNose (OPTN) and Intrexon Corporation (XON) Head to Head ReviewOptiNose (OPTN) and Intrexon Corporation (XON) Head to Head Review
www.americanbankingnews.com - November 24 at 8:24 AM
First Week Of XON July 2018 Options TradingFirst Week Of XON July 2018 Options Trading
www.thestreet.com - November 23 at 7:35 AM
Intrexon Corporation (XON) Forecasted to Post FY2017 Earnings of ($1.11) Per ShareIntrexon Corporation (XON) Forecasted to Post FY2017 Earnings of ($1.11) Per Share
www.americanbankingnews.com - November 23 at 7:28 AM
ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual MeetingZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting
finance.yahoo.com - November 20 at 12:27 PM
ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-OncologyZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology
finance.yahoo.com - November 18 at 10:31 AM
Stock Traders Buy High Volume of Intrexon Corporation Call Options (XON)Stock Traders Buy High Volume of Intrexon Corporation Call Options (XON)
www.americanbankingnews.com - November 17 at 3:28 AM
Featured Company News - Zymeworks Enters Into License Agreement with Janssen Biotech to Develop and Commercialize Next Generation Bispecific Antibody TherapeuticsFeatured Company News - Zymeworks Enters Into License Agreement with Janssen Biotech to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics
finance.yahoo.com - November 16 at 9:45 AM
Here's What You Need to Know About Intrexon's Third-Quarter 2017 EarningsHere's What You Need to Know About Intrexon's Third-Quarter 2017 Earnings
finance.yahoo.com - November 16 at 9:45 AM
Today’s Research Reports on Trending Tickers: Array BioPharma and Intrexon CorporationToday’s Research Reports on Trending Tickers: Array BioPharma and Intrexon Corporation
finance.yahoo.com - November 16 at 9:45 AM
Bill Miller, Kris Jenner share stocks theyve got their eye onBill Miller, Kris Jenner share stocks they've got their eye on
finance.yahoo.com - November 16 at 9:45 AM
AquaBounty wins Gold Leaf Award for Best “Emerging Agriculture Company” from BIOTECanadaAquaBounty wins Gold Leaf Award for Best “Emerging Agriculture Company” from BIOTECanada
finance.yahoo.com - November 16 at 9:45 AM
Insider Buying: Intrexon Corporation (XON) COO Acquires 2,000 Shares of StockInsider Buying: Intrexon Corporation (XON) COO Acquires 2,000 Shares of Stock
www.americanbankingnews.com - November 15 at 9:58 PM
$56.61 Million in Sales Expected for Intrexon Corporation (XON) This Quarter$56.61 Million in Sales Expected for Intrexon Corporation (XON) This Quarter
www.americanbankingnews.com - November 14 at 11:41 AM
Is Peak Permian Only 3 Years Away?Is Peak Permian Only 3 Years Away?
finance.yahoo.com - November 13 at 10:34 AM
Intrexon Corporation Target of Unusually High Options Trading (XON)Intrexon Corporation Target of Unusually High Options Trading (XON)
www.americanbankingnews.com - November 13 at 3:02 AM
Intrexon Makes New All-Time Low After Q3 MissIntrexon Makes New All-Time Low After Q3 Miss
www.benzinga.com - November 12 at 1:41 PM
Intrexon to Present at the Stifel 2017 Healthcare ConferenceIntrexon to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 12 at 1:41 PM
Edited Transcript of XON earnings conference call or presentation 9-Nov-17 10:30pm GMTEdited Transcript of XON earnings conference call or presentation 9-Nov-17 10:30pm GMT
finance.yahoo.com - November 12 at 1:41 PM
ZIOPHARM to Present at the Stifel 2017 Healthcare ConferenceZIOPHARM to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 12 at 1:41 PM
Intrexon Corporation (XON) Price Target Raised to $57.00Intrexon Corporation (XON) Price Target Raised to $57.00
www.americanbankingnews.com - November 12 at 11:46 AM
Intrexon Corporation (XON) Expected to Post Earnings of -$0.19 Per ShareIntrexon Corporation (XON) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - November 12 at 5:24 AM
Intrexon Corporation (XON) Earns "Buy" Rating from Northland SecuritiesIntrexon Corporation (XON) Earns "Buy" Rating from Northland Securities
www.americanbankingnews.com - November 11 at 12:36 AM
Why Intrexon Corporation Stock Got Crushed TodayWhy Intrexon Corporation Stock Got Crushed Today
www.fool.com - November 10 at 6:43 PM
Bank of America Corporation Lowers Intrexon Corporation (XON) Price Target to $21.00Bank of America Corporation Lowers Intrexon Corporation (XON) Price Target to $21.00
www.americanbankingnews.com - November 10 at 5:42 PM
Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into ... - Business Wire (press release)Oragenics Announces Closing of $3.3 Million Preferred Stock Private Placement and $3.4 Million Debt Conversion into ... - Business Wire (press release)
www.businesswire.com - November 9 at 10:31 AM
Why Intrexon Corporation (XON) Could Be A BuyWhy Intrexon Corporation (XON) Could Be A Buy
finance.yahoo.com - November 9 at 10:31 AM
ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent ActivitiesZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities
finance.yahoo.com - November 6 at 8:24 PM
Intrexon Corporation (XON) Receives Average Rating of "Hold" from BrokeragesIntrexon Corporation (XON) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 5 at 3:42 PM
Intrexon to Announce Third Quarter 2017 Financial Results on November 9thIntrexon to Announce Third Quarter 2017 Financial Results on November 9th
finance.yahoo.com - November 1 at 11:03 AM
ZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual MeetingZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 11:03 AM
Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich AtaxiaAgilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia
finance.yahoo.com - October 31 at 12:37 PM
Todays Research Reports on Trending Tickers: Intrexon Corporation and Valeant PharmaceuticalsToday's Research Reports on Trending Tickers: Intrexon Corporation and Valeant Pharmaceuticals
finance.yahoo.com - October 31 at 12:37 PM
Intrexon Corporation (XON) Set to Announce Quarterly Earnings on TuesdayIntrexon Corporation (XON) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:36 AM
ETFs with exposure to Intrexon Corp. : October 27, 2017ETFs with exposure to Intrexon Corp. : October 27, 2017
finance.yahoo.com - October 27 at 5:10 PM
ZIOPHARM Oncology to Host Third-Quarter 2017 Financial Results and Corporate Update Conference Call on November 6, 2017 at 4:30 p.m. ETZIOPHARM Oncology to Host Third-Quarter 2017 Financial Results and Corporate Update Conference Call on November 6, 2017 at 4:30 p.m. ET
finance.yahoo.com - October 27 at 7:48 AM
Comparing OncoSec Medical (ONCS) & Intrexon Corporation (XON)Comparing OncoSec Medical (ONCS) & Intrexon Corporation (XON)
www.americanbankingnews.com - October 27 at 7:14 AM
Intrexon Corporation (XON) Expected to Post Quarterly Sales of $55.17 MillionIntrexon Corporation (XON) Expected to Post Quarterly Sales of $55.17 Million
www.americanbankingnews.com - October 25 at 10:44 PM
Synthetic Biology Market to Reach 21.1 Billion USD by 2023 - IndustryARCSynthetic Biology Market to Reach 21.1 Billion USD by 2023 - IndustryARC
www.marketwatch.com - October 24 at 12:45 PM

SEC Filings

Intrexon (NYSE:XON) SEC Filings

DateFilerForm TypeView
12/07/2017
3:39 PM
Intrexon (Issuer)
Sabzevari Helen (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
View Filing
12/07/2017
3:36 PM
Bostick Thomas (Reporting)
Intrexon (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
View Filing
12/07/2017
3:33 PM
Intrexon (Issuer)
Walsh Robert F. III (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
View Filing
12/04/2017
3:35 PM
Intrexon (Issuer)
KIRK RANDAL J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
11/30/2017
6:59 PM
Intrexon (Reporting)
KIRK RANDAL J (Reporting)
ZIOPHARM ONCOLOGY INC (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
11/30/2017
3:20 PM
Intrexon (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing

Social Media

Financials

Intrexon (NYSE:XON) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intrexon (NYSE XON) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.